FSSAI questions 'lean muscle' claims of GLP-1 protein supplement Celevida GLP+
Representative image: FabianoAdvertising / Pixabay
On October 8, 2026, FSSAI sent show-cause notices to Dr Reddy's, Nestle Health Science and online sellers over health claims for the GLP-1-linked supplement Celevida GLP+.
What Happened
The Food Safety and Standards Authority of India (FSSAI), the country's food regulator, issued show-cause notices on October 8, 2026 over the marketing of Celevida GLP+, a high-protein nutritional supplement aimed at people taking GLP-1 and GIP weight-loss and diabetes medicines. The notices went to Dr Reddy's Laboratories and Nestle Health Science, whose joint venture launched the product in May 2026, as well as to online sellers Amazon India, Flipkart and Netmeds, and to contract manufacturer Tirupati Wellness. The companies have been asked to explain why action should not be taken against them under the Food Safety and Standards Act, 2006.
Key Facts
- FSSAI issued the show-cause notices on October 8, 2026.
- Those named include Dr Reddy's Laboratories, Nestle Health Science, Amazon India, Flipkart, Netmeds and Tirupati Wellness.
- Celevida GLP+ is a high-protein supplement marketed to people on GLP-1 and GIP therapies, a class of medicines used for weight loss and type 2 diabetes.
- The regulator questioned the line "High protein support for lean muscle preservation during GLP-1/GIP therapies" and the phrase "Help Maintain Lean Muscle".
- Other flagged claims, according to reports, concerned muscle strength, immunity, energy metabolism and the wording "imported from Europe for purity".
- FSSAI also raised concern that the brand name itself could suggest a link between a food supplement and prescription drug treatment.
- A show-cause notice is not a finding of violation; no response from the companies or final decision had been reported.
Why It Matters
GLP-1 medicines, which reduce appetite and help people lose weight, have become one of the biggest stories in global health. As more Indians use them, a market has grown around products that promise to protect muscle, energy or nutrition during treatment. Doctors have long noted that rapid weight loss can mean losing muscle as well as fat, so a claim about "lean muscle preservation" speaks directly to a real worry of patients.
That is exactly why the regulator is cautious. Under Indian food law, a food or supplement may not suggest that it treats, prevents or manages a disease or a specific medical condition unless such a claim is allowed. FSSAI's concern, as reported, is that phrases tying the product to a drug therapy, and a name that echoes the drug class, may lead buyers to think a supplement has a proven medical role. Reports say the regulator wants the companies to show why these claims should not be treated as misleading.
The notices also reach the online marketplaces, not only the makers. That matters because a large share of health and wellness products in India is now bought through apps and websites, where product pages repeat the maker's claims. Naming sellers signals that platforms can also be held to account for what they display.
For readers who value a food-first approach to health, the episode is a reminder to read labels with care. India's own food traditions put protein on the plate through everyday foods such as pulses, milk and curd, and anyone on a prescribed weight-loss medicine should take nutrition advice from their doctor or a qualified dietitian rather than from a product's packaging.
| Point | What was reported |
|---|---|
| Date of notices | October 8, 2026 |
| Product | Celevida GLP+ high-protein supplement |
| Maker | Dr Reddy's and Nestle Health Science joint venture, launched May 2026 |
| Main concern | Claims linking the product to GLP-1/GIP drug therapy and lean muscle preservation |
| Status | Show-cause notices; no final decision reported |
Impact
Short-term: The companies and sellers must respond to the regulator, and product listings and advertising may be reviewed or changed while the matter is examined.
Long-term: The case could shape how all brands market nutrition products to people on GLP-1 medicines in India, a fast-growing segment, and may push firms to support claims with evidence before making them.
Who is affected: People using or considering GLP-1 or GIP medicines; buyers of protein and wellness supplements; nutrition brands and pharmaceutical companies; and e-commerce platforms that sell health products.
Key Takeaway
India's food regulator has challenged a GLP-1-linked protein supplement's lean-muscle and related claims, asking its makers and sellers to justify them, though no violation has yet been established.
Questions and Answers
Has FSSAI banned Celevida GLP+?
No. FSSAI has issued show-cause notices asking the makers and sellers to explain why action should not be taken. That is a step in an inquiry, not a ban or a final ruling.
What exactly did the regulator object to?
According to reports, it questioned claims about preserving lean muscle during GLP-1 or GIP therapy, other claims on muscle strength, immunity and metabolism, the phrase "imported from Europe for purity", and whether the product name suggests a link to prescription drugs.
Why were Amazon, Flipkart and Netmeds included?
They sell the product online and display its marketing claims. Including them signals that the regulator expects platforms, not only manufacturers, to ensure that health claims shown to buyers comply with food law.
What should someone on a GLP-1 medicine do about nutrition?
They should follow advice from their doctor or a qualified dietitian, who can recommend enough protein and other nutrients from regular meals and decide whether any supplement is needed.
Disclaimer: Prepared by the Peepals newsroom from publicly available sources with AI assistance. Information is accurate to the best of our knowledge at the time of publication and may change. Images may be representative. Not professional advice. Report an error via our contact page.
Sourced and fact-checked by the Peepals Global Editorial Team
Reported, fact-checked and published by the Peepals Global Editorial Team.
